TABLE 2.
Respiratory morbidity of patients hospitalised in France for COVID-19 (1 March 2020 to 30 April 2020) or seasonal influenza (1 December 2018 to 28 February 2019) according to pulmonary comorbidity at admission
| CRF | Lung cancer | PH | Sleep apnoea | COPD | Emphysema | Asthma | Pulmonary sarcoidosis | ILD | CF | |
| COVID-19 | ||||||||||
| Patients | 1433 | 977 | 341 | 3581 | 4866 | 1426 | 3273 | 159 | 1611 | 20 |
| Pulmonary embolism | 36 (2.5)# | 44 (4.5) | 38 (11.1)# | 152 (4.2)# | 151 (3.1)# | 101 (7.1)# | 114 (3.5)# | 8 (5.0) | 93 (5.8)# | 0 (0.0) |
| VAP | 117 (8.2)¶ | 49 (5.0)¶ | 49 (14.4)# | 692 (19.3)# | 457 (9.4) | 237 (16.6)# | 354 (10.8)# | 30 (18.9)# | 311 (19.3)# | 1 (5.0) |
| Pneumocystis pneumonia | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Aspergillosis pneumonia | 13 (0.9) | 1 (0.1)¶ | 1 (0.3) | 18 (0.5) | 32 (0.7) | 17 (1.2) | 23 (0.7) | 0 (0.0) | 15 (0.9) | 1 (5.0) |
| Pleural empyema | 1 (0.1) | 6 (0.6) | 0 (0.0) | 3 (0.1)¶ | 3 (0.1) | 2 (0.1) | 2 (0.1) | 1 (0.6) | 3 (0.2) | 0 (0.0) |
| Lung abscess | 2 (0.1) | 6 (0.6) | 0 (0.0) | 5 (0.1) | 3 (0.1) | 6 (0.4) | 2 (0.1) | 0 (0.0) | 9 (0.6) | 0 (0.0) |
| Pneumothorax | 8 (0.6) | 10 (1.0) | 4 (1.2) | 29 (0.8) | 25 (0.5) | 39 (2.7) | 14 (0.4) | 1 (1.6) | 25 (1.6) | 1 (5.0) |
| ICU | 320 (22.3)¶ | 117 (12.0)¶ | 97 (28.5) | 1172 (32.7)# | 986 (20.6)¶ | 405 (28.4) | 640 (19.6)# | 53 (33.3)# | 527 (32.7)# | 2 (10.0) |
| In-hospital death | 413 (28.8)# | 402 (41.2)# | 96 (28.2)# | 672 (18.8)# | 1229 (25.3)# | 312 (21.8)# | 310 (9.5)# | 32 (20.1)# | 363 (22.5)# | 0 (0.0) |
| Seasonal influenza | ||||||||||
| Patients | 1830 | 431 | 247 | 1443 | 4637 | 553 | 2230 | 81 | 471 | 79 |
| Pulmonary embolism | 28 (1.5)# | 16 (3.7) | 6 (2.4)# | 16 (1.1)# | 59 (1.3)# | 11 (2.0)# | 14 (0.6)# | 1 (1.2) | 10 (2.1)# | 1 (1.3) |
| VAP | 250 (13.7)¶ | 39 (9.1)¶ | 17 (6.9)# | 138 (96.6)# | 423 (9.1) | 62 (11.2)# | 91 (4.1)# | 4 (4.9)# | 58 (12.3)# | 2 (2.5) |
| Pneumocystis pneumonia | 0 (0.0) | 2 (0.5) | 0 (0.0) | 1 (0.1) | 1 (0.0) | 0 (0.0) | 2 (0.1) | 2 (2.5) | 1 (0.2) | 0 (0.0) |
| Aspergillosis pneumonia | 16 (0.9) | 6 (1.4)¶ | 1 (0.4) | 10 (0.7) | 34 (0.7) | 11 (2.0) | 12 (0.5) | 1 (1.2) | 7 (1.5) | 4 (5.1) |
| Pleural empyema | 3 (0.2) | 1 (0.2) | 0 (0.0) | 5 (0.4)¶ | 3 (0.1) | 0 (0.0) | 2 (0.1) | 1 (1.2) | 3 (0.6) | 0 (0.0) |
| Lung abscess | 2 (0.1) | 3 (0.7) | 0 (0.0) | 2 (0.1) | 8 (0.2) | 2 (0.4) | 1 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Pneumothorax | 7 (0.4) | 3 (0.7) | 1 (0.4) | 6 (0.4) | 15 (0.3) | 13 (2.4) | 8 (0.4) | 0 (0.0) | 7 (1.5) | 2 (2.5) |
| ICU | 621 (33.9)¶ | 92 (21.4)¶ | 74 (30.0) | 376 (26.1)# | 1121 (24.2)¶ | 175 (31.7) | 274 (12.3)# | 12 (14.8)# | 122 (25.9)# | 4 (5.1) |
| In-hospital death | 201 (11.0)# | 87 (20.2)# | 28 (11.3)# | 77 (5.3)# | 383 (8.3)# | 39 (7.1)# | 55 (2.5)# | 5 (6.2)# | 65 (13.8)# | 1 (1.3) |
Data are presented as n or n (%). CRF: chronic respiratory failure; PH: pulmonary hypertension; COPD: chronic obstructive pulmonary disease; ILD: interstitial lung disease; CF: cystic fibrosis; VAP: ventilator-acquired pneumonia; ICU: intensive care unit. #: significantly more frequent in the COVID-19 group (p<0.05); ¶: significantly more frequent in the seasonal influenza group (p<0.05).